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Clinical practice guidelines (CPGs) have been defined as ‘system-
atically developed statements to assist practitioner and patient
decisions about appropriate healthcare for specific clinical
circumstances’ (Institute of Medicine, 1990). The aim is to inform
the clinician and the patient of the current best clinical practice in
a given situation, based on a synthesis of the available evidence.
The ‘Standards, Options and Recommendations’ (SOR) project
develops evidence-based CPGs in oncology and has been under-
taken by the French National Federation of Cancer Centers
(FNCLCC) since 1993 (Fervers et al, 1995). The project is a
collaboration between the FNCLCC (a Federation of the 20
French comprehensive cancer centres) and specialists from French
public universities, general hospitals and private clinics. The aim
of the project is to increase the quality and efficiency of care given
to cancer patients by developing, disseminating and implementing
CPGs. SORs are designed to provide a decision guide for cancer
specialists in the choice of strategies for the diagnosis, treatment
and follow-up of cancer patients. 
The FNCLCC represents the regional cancer centres (CRCCs)
as a collaborative body at national and international level and
coordinates activity in scientific, economic and social domains.
The CRCCs are public service hospitals and have a mission of
multidisciplinary cancer care, education and research. Twenty-five
percent of all cancer patients in France (240 000 new cases every
year) are managed within the CRCCs. The remainder are treated in
public universities, general hospitals and private clinics. 
The SOR project encompasses the progressive development of
CPGs for the initial management of cancer in adults and children,
for supportive care and control of symptoms in cancer patients and
for the standardization of ‘good clinical practice’ throughout the
various disciplines involved in cancer care. It has also undertaken the
development of CPGs specifically for nursing and paramedical staff,
as well as the provision of evidence-based information for patients.
GUIDELINE DEVELOPMENT PROCESS 
The guideline development process is based on literature review
and critical appraisal by specialists from the CRCCs, the French
public universities, general hospitals and private clinics, with feed-
back from practitioners in cancer care delivery. The methodology
and development process were defined in 1993 by the FNCLCC
(Fervers et al, 1995) based on the experience of various organiza-
tions who have been involved in guideline development, in partic-
ular the French National Agency for Accreditation and Evaluation
in Health (ANAES, formerly ANDEM) (Agence Nationale pour le
Développement de l’Evaluation Médicale, 1993; Agency for Health
Care Policy and Research, 1992). ANAES, a government-funded
agency, develops CPGs for various domains at the national level. 
The methodological approach combines systematic review with
expert judgement, rather than methods based entirely on either
scientific data or the opinion of experts (Mulrow, 1987; Woolf,
1992; Fervers et al, 1995; Browman et al, 1995). It thus provides
qualitative systematic reviews as compared to quantitative system-
atic reviews or meta-analyses. 
The guideline development process identifies eight separate
steps prior to final approval: topic selection, formation of a
working group, defining the questions, literature search, critical
appraisal, synthesis of the evidence, formulation of the recommen-
dations and finally independent, external review (Fervers, 2000). 
Topic selection 
The SOR project covers as a priority all aspects of first-line
management (including diagnosis, staging, prevention, first-line
treatment and follow-up) in all cancers, adult and paediatric. This
is the basis for topic selection by the executive committee of the
SOR project, in collaboration with multidisciplinary disease site
groups and the scientific committee of the SOR program. In addi-
tion, the CRCCs, ANAES or scientific societies can commission the
SOR programm to develop cancer guidelines for specific topics. 
Working groups 
The working groups for each subject are multidisciplinary, made
up of experts from the specialties involved in the management of a
given tumour type or a specific topic. This includes representatives
from the CRCCs, the French public universities, general hospitals,
private clinics and scientific societies. Each working group is
assisted by a methodologist who contributes to and coordinates the
drafting and editing SOR process, along with the organization of
working group meetings. The methodologists form part of the
organizational group of the SOR program (COSOR) and report to
a central project coordinator, who in turn sits on the executive
committee of the SOR project (see Figure 1). 
Refining the questions 
The first task of each group is to define specific and relevant ques-
tions for each clinical situation considered. This includes a defini-
tion of objectives, the population to be considered, the potential
diagnostic methods or therapeutic interventions utilized and 
the criteria with which to evaluate the interventions considered.
This forms the basis of the definition of the literature search
strategy. 
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The compilation of an exhaustive and relevant bibliography is a
key element in the formation of the SORs. This is based primarily
on published and indexed literature. The literature search is
performed by a professional information librarian and is carried
out according to standard procedures (Bonichon et al, 1998),
including the search of electronic databases (Medline, Cancerlit),
databases of systemic reviews (Cochrane library) and Internet sites
of organizations developing and/or evaluating guidelines. Details
of the strategy used for each SOR document are published in the full
guideline report of each SOR. 
Critical appraisal of the evidence 
Explicit criteria are used for the assessment of the validity of trial
results and the quality of the methodology according to the type
of publication (Guyatt et al, 1993, 1994, 1997; Oxman et al,
1993, 1994; Jaeschke et al, 1994a, 1994b; Laupacis et al, 1994;
Levine et al, 1994; Hayward et al, 1995). To improve methodo-
logical rigor, to limit bias in the selection of relevant studies and
to facilitate the data review process, critical appraisal checklists
have been developed for different types of publications (Fervers,
2000). The aim has been to achieve a balance between 
practicability and methodological rigor while acknowledging 
the time constraints of experts. The critical appraisal checklists
contain the criteria necessary for the assessment of the quality
and the clinical relevance of the information (Figure 2). 
Experts are required to state the reason if any evidence is
excluded. 
Synthesis of the evidence 
The relevant studies are tabulated to present the study method and
population, and the benefits and potential disadvantages of each
SOR: project methodology 9
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Figure 1 Organization of the SOR project. COSOR = Organising Committee for SOR10 B Fervers et al
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Reference:
Question Yes No Not possible to
determine or not
applicable
1.   Is the study randomized?
2.   Is it a prospective study?
3.   Is it a retrospective study?
4.   Are the primary end-points defined?
5.   Is the time of evaluation specified?
6.   Is the number of patients included in the study
      specified?
7.   Is the number of patients included in the analysis 
      specified?
      (the results relate to only a sub-section of patients included)
8.   Is the number of patients required specified?
9.   Have the authors answered the question initially asked
      according to the specified end-points?
10.   Have all the patients been analysed in the group to
        which they were initially allocated whether or not they
        completed treatment?('Intention-to-treat' analysis)
11.   Is the quality of the study generally satisfactory?
        If not, explain why.
12.   Are the results of this study to be included in the report or tables of a SOR document?
YES
In the case of an up-date, do the results change the standards, options or
recommendations of the SOR? NO
YES in what way?
NO, Why?SOR: project methodology 11
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Reference:
Patient characterstics (stage, age, etc)
Description of treatment in each study arm
Number of patients included
Number of patients evaluated
Primary end-points
• Tumour volume(complete or partial
     response)
         partial response (RP) in %
         complete response (CR) in %
• Survival (%, duration)
         relapse free
         without local recurrence
         without metastases
         event free
         overall
    (specify details)
• other, specify
Survival definitions
(median, mean or survival at x years)
Confidence intervals of primary end-point
P value of primary end-point
Definition of toxicity
Comments
arm A arm B arm C arm D
Put NS if not specified in the publication
Figure 2 (A) Critical appraisal checklist for therapeutic studies (B) data extraction form 12 B Fervers et al
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intervention. This is accompanied by comments and conclusions
as to the validity of the results. This facilitates a comparison of the
various interventions and provides the basis for the formulation of
the SORs. 
Formulation of the ‘Standards, Options and
Recommendations’ 
Based on the synthesis of the evidence, experts define the
‘Standards’, ‘Options’ and ‘Recommendations’ for a given clinical
situation. These are based on the best available evidence for that
condition. The differentiation of ‘Standards’ and ‘Options’ identi-
fies clinical situations where there exist strong indications or
contra-indications for a particular intervention (Standards) and
situations where there are several alternatives, none of which have
shown clear superiority over the others (Options) (Table 1). 
In any SOR, there can be several ‘Options’ for one clinical situ-
ation. ‘Recommendations’ allow for the weighting of Options
according to the available evidence. Several interventions can be
recommended for the same clinical situation. In this way, clini-
cians can make a choice according to specific clinical parameters,
e.g. local circumstances, skills, equipment, resources and patient
preferences. This ability to adapt the SOR according to local situa-
tions is acceptable if the reason for the choice is sufficiently trans-
parent and is crucial for successful implementation. Inclusion of
patients in clinical trials is an appropriate form of patient manage-
ment in oncology and is recommended frequently within the
SORs, in particular in situations where the evidence to support an
intervention is weak. 
In order to give the user information about the type of evidence
underlying any ‘Standard’, ‘Option’ or ‘Recommendation’, a clas-
sification of different levels of evidence was developed by the
FNCLCC based on previously published models (Canadian Task
Force on the Periodic Health Examination, 1988; Agence Nationale
pour le Développement de l’Evaluation Médicale, 1993; Sackett,
1989; American Society of Clinical Oncology, 1994; Agency for
Health Care Policy and Research, 1992). The level of evidence
depends not only on the type and quality of the studies reviewed,
but also on the concordance of the results (Table 2). When there is
no clear scientific evidence, a judgement is made according to the
professional experience and consensus of the expert group (expert
agreement). The latter must be confirmed by independent review
(see below). Experience has shown that classifications of levels of
evidence have limitations and risk providing positive support for
interventions based on poor-quality evidence (Woolf et al, 1996;
Fervers et al, 1998a). Therefore, the use of any level of evidence
needs to be accompanied by an explicit and transparent process for
the reporting of the underlying evidence. 
Structure of the SOR report 
All documents follow the same format with the critical appraisal of
the scientific data and summary tables for each clinical question
grouped into sections corresponding to diagnosis, staging, treat-
ment and follow-up. At the end of each section a summary
presents the Standards, Options and Recommendations, with
accompanying levels of evidence. 
Clinical algorithms 
The SORs are integrated into clinical pathways that are presen-
ted in the form of algorithms or decision trees (Figure 3). The 
algorithms are used as an aid for decision making (Hadorn et al,
1992). They provide a graphic representation of a situation,
focusing on the specific clinical decisions that must be made at
Table 1Definitions 
Standards 
Procedures or treatments for which results are known and which are considered of benefit, inappropriate or harmful by unanimous decision  
These represent strong indications or contraindications 
Options 
Methods for which the results of studies are known and which are considered of benefit, inappropriate or harmful by a majority 
They represent relative indications or contraindications 
Recommendations 
These are the decisions and choices made by the expert panel and the reviewers according to the different methods of evaluation 
They are used to rank the interventions by level of evidence when several methods are considered equally beneficial with respect to the same problem 
Table 2 Definition of level of evidence 
Level A 
There exists a meta-analysis of high standard or several randomized therapeutic trials of high standard which given consistent results 
Level B 
There exist studies, therapeutic trials, quasi-experimental trials, or comparisons of populations, of which the results are consistent when considered together 
Level C 
There exist studies, therapeutic trials, quasi-experimental trials or comparisons of populations, of which the results are not consistent when considered together 
Level D 
Either the scientific data does not exist or there is only a series of cases 
Expert agreement 
The data does not exist for the method concerned but the experts are unanimous in their judgement SOR: project methodology 13
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Diagnosis
and staging
Surgery
Advanced
stage disease
Limited stage
disease
Advanced stage epithelial ovarian cancer
Residual disease
after surgery?
yes no
Standard
platin based intravenous polychemotherapy
Options
• platin and paclitaxel (intravenous)
• platin and cyclophosphamide and/or
  doxorubicin (intravenous)
• cisplatin (intraperitoneal) combined with
  cyclophosphamide (intravenous) if
  residual disease < 2 cm
Standard
there is no standard
Options
• platin-based chemotherapy
• abdomino-pelvic external
  beam radiotherapy
Combination chemotherapy containing a platin given intravenously is standard treatment 
for advanced disease (stages IIB, IIC, III) with residual disease after surgery. The
addition of a platin to a combination without platin increases overall survival (level of 
evidence A). There does not appear to be a significant difference in terms of survival
between cisplatin and carboplatin (level of evidence A). When paclitaxel has not been
used as first line chemotherapy, its use is recommended in the case of relapse (expert
agreement)
The randomized trials having evaluated paclitaxel in combination as first line therapy are
shown in Table 10. The GOG study [MCGUIRE1996] compared the combination of 
paclitaxel (135 mg/m2 given as an infusion over 24 hours)-cisplatin, with 
cyclophosphamide-cisplatin, both given 3 weekly, in 386 patients presenting with
residual post-operative disease of > one centimetre. The results showed a statistically 
significant benefit in favour of the paclitaxel-cisplatin combination in terms of clinical
response, overall survival and relapse-free survival
Reference
Median
survival
(p)
Median
relapse free
survival (p)
Patient's
characteristics
N Treatment
Median
follow up
[MCGUIRE
1996]
CDDP + cyclo.
vs
CDDP+ paclit.
202
vs
184
Stage III
residual disease
> 1 cm
stage IV
13 month
vs
18 month
P<0.001
24 month
vs
38 month
P<0.001
37
month
[MCGUIRE1996]. McGuire WP, Hoskins WJ, Brad MF, Kucera PR, Partridge
EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and
cisplatin compared with paclitaxel and cisplatin in patients with stage III and
stage IV ovarian cancer [see comments]. N Engl J Med 1996;334(1):1–6
Abstract
ABSTRACT  MEDLINE  copyright NLM)
We compared two comminations, cisplatin and cyclophosphamide and cisplatin
and paclitaxel, in women the ovarian cancer. METHODS. We randomly
assigned.....
Corresponding Medline
abstract (if available)
Corresponding
reference
Comparatives
tables
Critical appraisal of
the literature
Standards, Options and
Recommendations
with levels of evidence
Algorithm with clinical
decisions that must be
made at every stage
Stages of diagnosis
treatment and follow-up
Standards, Options
Figure 3 Methods of access to different levels of information of SOR, example algorithm (epithelial ovarian cancer) each stage in the management of a particular disease, that is in
prevention, diagnosis, staging, treatment and follow-up (Margolis,
1983). The development of these ‘decision trees’ is an integral part
of the guideline process and a key element of the SOR document
(Grol et al, 1998). They facilitate the identification of the principle
Standards and Options and refer directly to the relevant literature
appraisal in the SOR document to give, as required, more details
regarding the recommended practices (Figure 3). Along with the
summaries of each section, the decision trees give a convenient
practical guide for the management of each major tumour type. 
Independent review 
This is undertaken using specific criteria developed for systematic
reviews (Mulrow, 1987), as well as quality criteria referring more
specifically to the guideline development and reporting process
(Institute of Medicine, 1992; Cluzeau et al, 1999; AGREE
Collaborative Group, 2000). 
A questionnaire is sent to appropriate specialists who have not
been involved in the guideline development process within the
CRCCs, in relevant scientific societies and in the public and
private sectors (Figure 4). They are asked to evaluate the quality of
the SORs and whether they are in agreement with them. In the case
of comments or reservations, a detailed written justification is
requested, calling on relevant references from the literature and/or
experience of the doctor. The relevance and the scientific data to
support suggested changes are reviewed by the working group. In
the case of major disagreement on an important topic, a second
review is organized. The review process requires approval of the
SOR documents by the medical committee in each CRCC. 
Guideline dissemination 
The SOR documents are published in electronic form as a CD-
ROM and in print in the form of monographs and articles. Some
are available on the Internet (www.fnclcc.fr). The documents are
sent to all CRCCs via each director, to practitioners who provided
feedback, to members of collaborating scientific societies within
and outside the CRCCs and to coordinators of regional cancer
networks. Pharmaceutical companies are sent copies for distribu-
tion outside the CRCCs. Information on new SORs and the SOR
catalogue are sent regularly by Internet mailing and to cancer
centres, medical journals, the health department, etc. The recommen-
dations are presented regularly at conferences and meetings. 
To date, CD-ROM has been the main vehicle for dissemination.
A navigation method has been developed, based on the structure of
the SOR documents and the clinical algorithims. This facilitates a
problem-based approach using the clinical algorithms as the main
entry-point into the document, with hypertext links giving access
to the different levels of information ranging from the most
straightforward to the most complex. This is possible because of
the identical structure of each of the SOR documents (Figure 3).
When it exists, the corresponding Medline abstract can be
accessed. The project is indebted to the National Library of
Medicine and the National Institute of Health and of Medical
Research (INSERM) who have authorized the use of Medline
abstracts in the SOR CD-ROM. Publication details are listed in
Appendix 1. 
Guideline update 
Updating of clinical guidelines is a continuous process crucial for
the integration of new evidence. The update process is based on
literature searches performed on a regular basis. Depending on the
type of evidence identified and its consistency with the evidence
used to define the current SOR, different update strategies have
been defined. Identification of data that may have a major impact
on current guidelines will result in an ‘urgent updating process’.
‘Global updating’ is performed on a regular basis and allows for
the integration of new evidence as it becomes available. The
updating process also focuses on specific clinical questions of high
priority. A mail survey is undertaken to seek views of practitioners
in order to prioritise topics to be addressed in the update process.
A formal questionnaire has been developed to facilitate the
process in which key points (e.g. severity and frequency of the
target condition, uncertainty about appropriate practice, contro-
versy regarding interpretation of data) are scored. 
Sources of funding 
The SOR program has an annual budget of 6.9 million French
francs (1.05 million Euros) and is funded primarily by the
FNCLCC through contributions from each of the CRCCs and by
grants from a major cancer charity, the National League against
Cancer. Other sources of funding include the university hospitals,
Ministry of Health, private clinics and scientific societies. Private
industry has no financial, organizational or scientific participation
in the guideline development process, although financial contribu-
tions are received from pharmaceutical companies to aid the
dissemination of the SOR documents outside the CRCCs. The
work of all experts is voluntary. There is no personal remuneration
for the formulation or review of the SOR documents. 
ACHIEVEMENTS TO DATE 
More than 1700 practitioners (doctors, pharmacists and biologists)
have contributed to the project as members of working groups or
as reviewers; 43% from the CRCCs, 43% from universities or
general hospitals and 14% from the private sector (Fervers et al,
1998b). A total of 45 guidelines have been developed and
published since 1993. The first CD-ROM was produced in 1995.
A second CD-ROM containing new chapters plus updated
versions published in 1998 had the equivalent of 5000 text pages
including 740 tables, 270 clinical algorithms, 9560 bibliographic
references, 5140 abstracts and 26 000 hypertext links. More than
5000 CD-ROMs were distributed in 1998. A total of 10 mono-
graphs, focusing on specific topics, have been published since (see
Appendix 1). 
Four thousand copies of the monographs of the most frequent
cancers (colon, rectum, breast cancer and ovarian cancer) have
been distributed. SORs are published every second month in the
Bulletin of Cancer and in other French medical journals in collab-
oration with the French Society of Cancer. A number of SORs
are being translated into English for submission to international
journals. 
Full versions of all documents are available from the FNCLLC.
All SORs will soon be accessable on the FNCLCC web site
(www.fnclcc.fr). 
The program has been judged as successful on the basis of user
awareness and utilization. A formal survey designed to evaluate
14 B Fervers et al
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dissemination, awareness and the use of the guidelines involving
representative cancer specialists from the 20 CRCCs was under-
taken in 1998. This showed a high rate of awareness of the SOR
program (98.3%) and that the SOR documents had been dissemi-
nated widely. Ninety percent of specialists surveyed had received
the SOR guidelines. The majority (95%) of the practitioners used
the SOR in practice, during multidisciplinary (33%) or individual
(27%) decision-making processes. The SORs were also being used
as a source of information for teaching (20%) and for finding
evidence (20%).
CONCLUSION 
The aim of the SOR project is to provide cancer care specialists
with information on the current best clinical practice in a given
situation, based on a synthesis of the available evidence by a
multidisciplinary expert panel. 
The project has evolved over time as a consequence of practi-
tioner-led initiatives to achieve a balance between methodological
rigor and practicability. CPGs cannot replace clinical reasoning
based on experience. An explicit and transparent approach in the
guideline development and reporting process is necessary to 
show how underlying ‘evidence judgements’ and ‘preference
judgements’ have been made (Eddy, 1992). This is particularly
important for topics in which the evidence is weak. 
Routine implementation of such guidelines remains a major
challenge. Implementation of SORs at local and regional level has
been shown to be effective (Ray-Coquard et al, 1997). However,
there is currently no mechanism for the routine implementation of
SORs. Representatives of all potential users at national level are
encouraged to become involved in the project as early as possible
to improve acceptance and implementation. Implementation strat-
egies have to take into account local circumstances (Davis et al,
1995; Oxman et al, 1995). The adoption of the SOR guidelines by
clinicians at local and regional level is an important step in
successful implementation. This is one of the major aims of the
regional cancer network of CRCCs in France. 
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